What is the level of liabilities of AstraZeneca this year?
AstraZeneca has a debt balance of 61.98 B USD this year.
AstraZeneca Liabilities 2025
AstraZeneca Liabilities
61.98 B USD
Ticker
AZN.L
ISIN
GB0009895292
WKN
886455
In 2025, AstraZeneca's total liabilities amounted to 61.98 B USD, a 4.26% difference from the 59.45 B USD total liabilities in the previous year.
AstraZeneca Aktienanalyse
What does AstraZeneca do?
AstraZeneca PLC is a globally operating pharmaceutical company with its headquarters in England. The company was founded in 1999 through the merger of the Swedish company Astra AB and the British Zeneca Group PLC. Today, AstraZeneca employs more than 70,000 people and operates in over 100 countries. AstraZeneca specializes in the development, manufacturing, and marketing of pharmaceutical products. The company focuses primarily on oncology, cardiovascular and metabolic diseases, respiratory diseases, and autoimmune diseases. AstraZeneca is divided into various business segments. The oncology segment is a major focus of the company. Here, medications for various types of cancer are developed and manufactured. One particularly well-known product is the breast cancer medication Tamoxifen. In the cardiovascular and metabolic diseases segment, AstraZeneca offers various medications for heart and circulatory diseases as well as diabetes. One of the most well-known medications is Crestor, which is used to lower cholesterol levels. Another important area for AstraZeneca is respiratory diseases. Medications for the treatment of asthma and chronic obstructive pulmonary disease (COPD) are developed and manufactured here. The medication Pulmicort is particularly well-known among asthma patients. Finally, AstraZeneca is also active in the field of autoimmune diseases. Medications against lupus erythematosus and rheumatoid arthritis are developed and manufactured here. AstraZeneca strives to improve healthcare worldwide through research and development of new medications. The company works closely with universities and research institutions and invests billions of dollars annually in research and development. AstraZeneca also pursues a sustainable business strategy and emphasizes acting environmentally and socially responsibly. The company is committed to reducing CO2 emissions and minimizing waste production. Over the years, AstraZeneca has received numerous awards and prizes, including the Sunday Times Innovation Award of the Decade, the Fierce Biotech Award for the medication Tagrisso, and the Prix Galien USA Award for Crestor. AstraZeneca aims to develop innovative medications that improve the lives of patients and advance healthcare worldwide. The company believes in a sustainable business strategy and actively promotes environmental and social responsibility. AstraZeneca will remain an important player in the global pharmaceutical industry in the future. AstraZeneca ist eines der beliebtesten Unternehmen auf Eulerpool.com.Liabilities Details
Assessing AstraZeneca's Liabilities
AstraZeneca's liabilities constitute the company's financial obligations and debts owed to external parties and stakeholders. They are categorized into current liabilities, due within a year, and long-term liabilities, which are due over a longer period. A detailed assessment of these liabilities is crucial for evaluating AstraZeneca's financial stability, operational efficiency, and long-term viability.
Year-to-Year Comparison
By comparing AstraZeneca's liabilities year-over-year, investors can identify trends, shifts, and anomalies in the company’s financial positioning. A decrease in total liabilities often signals financial strengthening, while an increase might indicate enhanced investments, acquisitions, or potential financial strain.
Impact on Investments
AstraZeneca's total liabilities play a significant role in determining the company's leverage and risk profile. Investors and analysts examine this aspect meticulously to ascertain the firm’s ability to meet its financial obligations, which influences investment attractiveness and credit ratings.
Interpreting Liability Fluctuations
Shifts in AstraZeneca’s liability structure indicate changes in its financial management and strategy. A reduction in liabilities reflects efficient financial management or debt payoffs, while an increase may suggest expansion, acquisition activities, or accruing operational expenses, each carrying distinct implications for investors.
Frequently Asked Questions about AstraZeneca stock
What were the liabilities of AstraZeneca compared to the previous year?
The liabilities of AstraZeneca have increased by 4.26% increased compared to the previous year.
What are the consequences of high debt for investors of AstraZeneca?
High liabilities can pose a risk for investors of AstraZeneca, as they can weaken the company's financial position and impair its ability to meet its obligations.
What consequences do low liabilities have for investors in AstraZeneca?
Low liabilities mean that AstraZeneca has a strong financial position and is able to meet its obligations without overburdening its finances.
How does an increase in liabilities of AstraZeneca affect the company?
An increase in liabilities of AstraZeneca can lead to the company having more obligations and potentially find it more difficult to meet its financial commitments.
How does a reduction in the liabilities of AstraZeneca affect the company?
A decrease in the liabilities of AstraZeneca can lead to the company having fewer obligations and a stronger financial position, which can make it easier for the company to fulfill its financial commitments.
What are some factors that influence the liabilities of AstraZeneca?
Some factors that can influence the liabilities of AstraZeneca include investments, acquisitions, operating costs, and sales development.
Why is the level of liabilities of AstraZeneca so important for investors?
The liabilities of AstraZeneca are important for investors as they serve as an indicator of the company's financial stability and provide investors with information on how the company meets its financial obligations.
What strategic measures can AstraZeneca take to modify the liabilities?
To change its liabilities, AstraZeneca can take measures such as cost savings, increasing revenue, selling assets, raising investments, or forming partnerships. It is important for the company to conduct a thorough review of its financial situation to choose the best strategic actions.
How much dividend does AstraZeneca pay?
Over the past 12 months, AstraZeneca paid a dividend of 2.35 USD . This corresponds to a dividend yield of about 1.69 %. For the coming 12 months, AstraZeneca is expected to pay a dividend of 0.56 USD.
What is the dividend yield of AstraZeneca?
The current dividend yield of AstraZeneca is 1.69 %.
When does AstraZeneca pay dividends?
AstraZeneca pays a quarterly dividend. This is distributed in the months of March, September, March, September.
How secure is the dividend of AstraZeneca?
AstraZeneca paid dividends every year for the past 27 years.
What is the dividend of AstraZeneca?
For the upcoming 12 months, dividends amounting to 0.56 USD are expected. This corresponds to a dividend yield of 0.4 %.
In which sector is AstraZeneca located?
AstraZeneca is assigned to the 'Health' sector.
Wann musste ich die Aktien von AstraZeneca kaufen, um die vorherige Dividende zu erhalten?
To receive the latest dividend of AstraZeneca from 9/9/2024 amounting to 0.776 USD, you needed to have the stock in your portfolio before the ex-date on 8/8/2024.
When did AstraZeneca pay the last dividend?
The last dividend was paid out on 9/9/2024.
What was the dividend of AstraZeneca in the year 2024?
In the year 2024, AstraZeneca distributed 2.346 USD as dividends.
In which currency does AstraZeneca pay out the dividend?
The dividends of AstraZeneca are distributed in USD.
Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.
The AstraZeneca stock can be added to a savings plan with the following providers: Scalable Capital and Consorsbank
Andere Kennzahlen von AstraZeneca
Our stock analysis for AstraZeneca Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of AstraZeneca Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.
